AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

Core Insights - The pharmaceutical company experienced a 14% year-on-year increase in third-quarter core earnings per share [1] - Revenue for the company rose to $15.19 billion, up from $13.57 billion [1]